Andere Sprachen Nascent Biotech, Inc.

Aktien

A2PW03

US63108Q1013

NBIO

Markt geschlossen - OTC Markets Andere Börsenplätze 19:30:28 25.06.2024			% 5 Tage	% 1. Jan.
0,0885 ^USD	-1,56 %		-1,67 %	-48,81 %

16.04.	Nascent Biotech, Inc. bereitet sich mit einem neuen Produktionslauf auf die pivotale Phase II Forschung vor	CI
19.03.	Nascent kooperiert mit Hypospray Pharma kündigt Zusammenarbeit zur Entwicklung eines alternativen Verabreichungsmechanismus für Patienten an, die von Pritumumab profitieren können	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	17.04.
Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	16.04.
Nascent Collaborates With Hypospray Pharma Announces Collaboration to Develop an Alternative Delivery Mechanism for Patients Who Can Benefit from Pritumumab	19.03.
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14.02.
Nascent Biotech and Manhattan Biosolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates	06.02.
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is significantly under Valued	10.01.
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk	20.12.
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09.11.
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer	22.08.23
Nascent Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	18.08.23
Nascent Biotech, Inc. Auditor Raises 'Going Concern' Doubt	03.07.23
Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	29.06.23
Nastcent Biotech, Inc. and BioRay Pharmaceutical Co Mutually Terminates the License Agreement	30.05.23
Nascent Biotech : Termination of Material Agreement - Form 8-K	30.05.23
NASCENT BIOTECH INC. : Other Events, Financial Statements and Exhibits (form 8-K)	09.05.23
Nascent Biotech, Inc. Announces the Completion of Its Phase1 Clinical Trials	28.02.23
NASCENT BIOTECH INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERTIONS (form 10-Q)	14.02.23
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14.02.23
NASCENT BIOTECH INC. : Other Events, Financial Statements and Exhibits (form 8-K)	26.01.23
Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial	25.01.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Nascent Biotech, Inc.

Aktien

A2PW03

US63108Q1013

NBIO

Andere Sprachen

Filter